Eitan Machover - Medigus Independent Director

MDGS Stock  USD 2.84  0.16  5.97%   

Director

Mr. Eitan Machover was appointed as Independent Director of the Company., effective September 29, 2016. Mr. Machover has more than 30 years of leadership experience in healthcare, having held various business development and MA positions at GE Capital in the U.S., Europe and Asia. He headed business development activities at GE Healthcare in Europe, where he oversaw largescale acquisitions. In addition, he led integrations into GE Israeli operations and was later named the National Executive for General Electric Israel, overseeing all of GE activities in the country. Since then, Mr. Machover coestablished MediTech Advisors, where he managed two U.S. based medical device venture funds, and also served as CEO of Wellsense, Inc. a U.S. medical device company. Currently, he is the principal and owner of EM Advisory Service, Ltd. an Israelbased executive search firm since 2016.
Age 55
Tenure 8 years
Professional MarksMBA
Address 10 Hanechoshet, Tel Aviv, Israel, 6971072
Phone972 73 370 4691
Webhttps://www.medigus.com
Machover holds a BS in Business Communications from Emerson College and an MBA from Boston College.

Medigus Management Efficiency

The company has return on total asset (ROA) of (0.0663) % which means that it has lost $0.0663 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3072) %, meaning that it created substantial loss on money invested by shareholders. Medigus' management efficiency ratios could be used to measure how well Medigus manages its routine affairs as well as how well it operates its assets and liabilities. Return On Capital Employed is likely to drop to -0.22 in 2024. Return On Assets is likely to drop to -0.1 in 2024. At this time, Medigus' Asset Turnover is comparatively stable compared to the past year.
The company currently holds 10.13 M in liabilities with Debt to Equity (D/E) ratio of 0.27, which may suggest the company is not taking enough advantage from borrowing. Medigus Ltd ADR has a current ratio of 1.35, which is within standard range for the sector. Debt can assist Medigus until it has trouble settling it off, either with new capital or with free cash flow. So, Medigus' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Medigus Ltd ADR sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Medigus to invest in growth at high rates of return. When we think about Medigus' use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

DIRECTOR Age

Mary HoeltzelCigna Corp
N/A
Peter NeupertLaboratory
65
Michael FernandezMednax Inc
66
Manuel KadreMednax Inc
54
William ZollarsCigna Corp
70
Roman MartinezCigna Corp
71
Gary GillilandLaboratory
63
Dipchand NisharGuardant Health
N/A
Robert MittelstaedtLaboratory
74
JeanLuc BelingardLaboratory
72
Garheng KongLaboratory
45
Enrique SosaMednax Inc
79
Stanley MeresmanGuardant Health
71
Donna ZarconeCigna Corp
63
Kerrii AndersonLaboratory
63
John PartridgeCigna Corp
71
Jeffrey DavisLaboratory
57
Sanders WilliamsLaboratory
69
Jane HenneyCigna Corp
69
Samir KaulGuardant Health
44
Eric WisemanCigna Corp
65
Medigus Ltd., a technology-based company, provides medical-related devices and products in the United States, Europe, China, Israel, and internationally. Medigus Ltd. was incorporated in 1999 and is headquartered in Tel Aviv-Yafo, Israel. Medigus operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 26 people. Medigus Ltd ADR (MDGS) is traded on NASDAQ Exchange in USA. It is located in 10 Hanechoshet, Tel Aviv, Israel, 6971072 and employs 77 people. Medigus is listed under Health Care Equipment & Supplies category by Fama And French industry classification.

Management Performance

Medigus Ltd ADR Leadership Team

Elected by the shareholders, the Medigus' board of directors comprises two types of representatives: Medigus inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Medigus. The board's role is to monitor Medigus' management team and ensure that shareholders' interests are well served. Medigus' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Medigus' outside directors are responsible for providing unbiased perspectives on the board's policies.
Ilan Oren, Executive Officer
Efrat Venkert, External Director
Anat Naschitz, Director
Yaron Silberman, Chief Ltd
Ori Hershkovitz, External Director
Yair Rabinovitch, Director
Menashe Sonnenschein, Vice President - Operations
Gilad Mamlok, CFO
Christopher Rowland, CEO and Director
Eitan Machover, Independent Director
Minelu Sonnenschein, VP of Operations
Oded Yatzkan, Director of Fin. and Accounting and VP
Nissim Darvish, Chairman of the Board
Jeremy Starkweather, Director of Sales, Director of Marketing-United States
Yuval Yanai, Director
Aviel Shapira, Medical Director
Yair Rabinowitch, Director
Liron Carmel, Chief Officer
Erez Haimovitz, Director
Tali Dinar, Chief Officer
Doron Birger, Director
Tatyana Yossef, Controller
Yaron Zilberman, Vice President - Sales and Marketing

Medigus Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Medigus a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Medigus Ltd ADR is a strong investment it is important to analyze Medigus' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Medigus' future performance. For an informed investment choice regarding Medigus Stock, refer to the following important reports:
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Medigus Ltd ADR. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price.
Note that the Medigus Ltd ADR information on this page should be used as a complementary analysis to other Medigus' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.

Complementary Tools for Medigus Stock analysis

When running Medigus' price analysis, check to measure Medigus' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Medigus is operating at the current time. Most of Medigus' value examination focuses on studying past and present price action to predict the probability of Medigus' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Medigus' price. Additionally, you may evaluate how the addition of Medigus to your portfolios can decrease your overall portfolio volatility.
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Is Medigus' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Medigus. If investors know Medigus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Medigus listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(8.70)
Revenue Per Share
67.313
Quarterly Revenue Growth
0.527
Return On Assets
(0.07)
Return On Equity
(0.31)
The market value of Medigus Ltd ADR is measured differently than its book value, which is the value of Medigus that is recorded on the company's balance sheet. Investors also form their own opinion of Medigus' value that differs from its market value or its book value, called intrinsic value, which is Medigus' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Medigus' market value can be influenced by many factors that don't directly affect Medigus' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Medigus' value and its price as these two are different measures arrived at by different means. Investors typically determine if Medigus is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Medigus' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.